An Open-Label Randomized Phase 2 Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Advanced Breast Cancer
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-Free Survival
Baseline up to month 12
No
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
B1271005
NCT01658176
January 2013
April 2015
Name | Location |
---|